# AMARIN CORP PLCUK (AMRN) — Financial Analysis

**Exchange:** Nasdaq  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-17  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/amrn/thesis · /memo/amrn

## Financial Snapshot

### Step 04 — Financial Quality
#### Amarin Corporation plc (AMRN)
**Prepared:** June 2026 | **Classification:** Facts unless noted | **Step:** 04 of 20

---

#### 1. Accounting Quality Assessment

##### Revenue Recognition

Amarin's revenue recognition follows ASC 606 (Revenue from Contracts with Customers). Key policies:

**US Product Revenue:**
Revenue is recognized upon transfer of control to wholesalers — typically when product is shipped and accepted. Amarin must estimate and accrue significant variable consideration at the point of revenue recognition:
- Chargebacks (the difference between Amarin's list price and the contracted price paid by wholesaler to a PBM or government entity)
- Rebates to PBMs under formulary contracts
- Co-pay assistance (Amarin's patient programs reduce patient out-of-pocket; Amarin bears the cost)
- Product returns (estimated based on historical return rates)
- Medicaid rebates (government-mandated on Medicaid-covered prescriptions)

**Assessment:** The gross-to-net adjustment calculation for a branded drug in a highly genericized category is inherently complex. Amarin's net selling price is substantially below list price. Gross-to-net percentage is not explicitly disclosed in 10-K MD&A, but based on industry norms for branded drugs with active PBM rebate programs, gross-to-net adjustments are likely 40-60%+ of gross revenue. Any error in estimating PBM rebate liability could materially misstate revenue. There is no specific evidence of manipulation, but this is an area requiring audit scrutiny. [S1, Judgment]

**International/Licensing Revenue:**
Upfront licensing fees and milestones are recognized when or as the distinct performance obligation is satisfied. The Q2 2025 spike ($72.7M vs. $42-50M in surrounding quarters) reflects what appears to be immediate recognition of the Recordati upfront payment upon execution of the June 2025 licensing agreement — appropriate under ASC 606 if the license was a distinct performance obligation satisfied at a point in time. Ongoing supply revenue is recognized as product is delivered. Royalties are recognized when underlying partner sales occur [S1].

**Accounting quality assessment — Revenue: MODERATE CONCERN.** Gross-to-net estimates for branded pharma are legitimately complex and subject to management judgment. The company's accrued expenses balance ($149.1M at FY2025 year-end) is large relative to revenue ($213.6M) — a portion of this reflects accrued rebates and chargebacks. A revision in gross-to-net estimates could swing revenue by 5-15%. However, auditors (EY or PwC — Amarin uses a Big 4 auditor) review these estimates, and no restatements have occurred.

##### Inventory Valuation

VASCEPA/VAZKEPA has pharmaceutical product dating (expiry dates). Inventory is carried at the lower of cost or net realizable value (NRV). **This is the single highest-quality concern in the financial statements.**

Key facts:
- FY2025 inventory: $195.9M (92% of annual revenue!) [S1]
- FY2024 inventory: $230.8M (with significant write-down impact visible in FY2024 COGS: $147.2M on $228.6M revenue = 64.4% COGS ratio vs. 43% in FY2025)
- 10-K disclosure: ~50% of inventory approved for North America, ~50% for international supply [S1]
- Product dating risk: VASCEPA capsules have finite shelf life; if product cannot be sold before expiry, it must be written down

The FY2024 gross margin collapse to 35.6% was partially driven by inventory charges. The FY2025 partial recovery to 56.6% suggests the worst write-downs occurred in FY2024, but the $195.9M remaining inventory still carries significant write-down risk given:
- Annual revenue of ~$213M → if even 20% of inventory expires/cannot be sold, that is a $39M charge (18% of current revenue)
- Ongoing US volume declines reduce the ability to sell North American inventory
- International ramp timing (Recordati) is uncertain [S1, S2, Judgment]

**Accounting quality assessment — Inventory: HIGH CONCERN.** The $195.9M inventory balance is the most material balance sheet risk item. Any slowdown in Recordati's European commercial ramp or additional US volume deterioration could trigger further write-downs.

##### Stock-Based Compensation

SBC was $13.9M in FY2025 (per 10-K), declining from $17.7M (FY2024) and $15.6M (FY2023) — consistent with the headcount reduction trend [S1]. SBC is excluded from some non-GAAP presentations; the magnitude relative to operating losses is significant (SBC is ~36% of the absolute operating loss), so non-GAAP adjustments meaningfully change the picture:

- GAAP operating loss FY2025: $(50.2M)
- Less: SBC: +$13.9M
- Less: Restructuring charges: +$36.2M (largely one-time)
- Adjusted (non-GAAP) operating loss (ex-restructuring, ex-SBC): approximately $(0.1M) — near breakeven [Estimate]

**Assessment:** The magnitude of restructuring charges in FY2025 is legitimate (reflecting genuine one-time cost of European team elimination) but investors should note that Amarin has had significant restructuring charges in multiple consecutive years (2023, 2025), which is a yellow flag when assessing "one-time" vs. structural costs.

---

#### 2. Statement-Quality Adjustments

To normalize for comparison across periods, the following adjustments are appropriate:

| Item | FY2025 | FY2024 | FY2023 | Treatment |
|------|--------|--------|--------|-----------|
| Restructuring charges | $36.2M | ~$0M | $11.0M | Add back — genuinely one-time (European team exit) |
| Inventory write-downs | [Small] | Large (estimated ~$55M) | Modest | Add back in year incurred; monitor going forward |
| Stock-Based Compensation | $13.9M | $17.7M | $15.6M | Judgment call — SBC is a real economic cost; add back only for cash earnings analysis |
| Licensing fee recognition (Q2 2025) | $25-30M [Estimate] | — | — | Consider separately from recurring revenue — milestone is real but non-recurring in that form |
| Interest income | $10.9M | $13.4M | $11.9M | Include — not a distortion; reflects genuine asset |

*[Note: FY2024 inventory write-down magnitude is estimated from the gross margin collapse (FY2024 gross margin 35.6% vs. 56.6% in FY2025 and 53.9% in FY2023); Amarin does not separately disclose inventory write-down line items in the income statement — they flow through COGS.]*

**Normalized operating loss (FY2025, excluding restructuring + inventory write-downs):**
- GAAP operating loss: $(50.2M)
- Add: Restructuring: +$36.2M
- Normalized operating loss: $(14.0M)
- Add: SBC (for cash earnings): +$13.9M
- Cash operating income (ex-SBC): approximately $(0.1M) — near breakeven [Estimate]

---

#### 3. Normalized Earnings Analysis

##### GAAP vs. Cash Earnings vs. Operating Burn

| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|--------|--------|--------|--------|--------|
| GAAP Net Income (Loss) | $(38.8M) | $(82.2M) | $(59.1M) | $(105.8M) |
| GAAP EPS (diluted) | $(1.60)/sh | $(3.60)/sh | $(3.00)/sh | $(5.20)/sh |
| Operating Cash Flow | +$6.7M | $(31.0M) | +$6.9M | $(180.7M) |
| Free Cash Flow | +$9.3M | $(31.0M) | +$6.9M | $(180.7M) |
| FCF per Share | +$0.45/sh | $(1.51)/sh | +$0.34/sh | $(9.01)/sh |
| Non-GAAP EPS (per mgmt) | +$0.04/sh | n/a | n/a | n/a |

[S2, S3]

**Analysis:**

The divergence between GAAP net loss and positive operating cash flow in FY2025 and FY2023 requires explanation:
- **FY2025:** GAAP net loss $(38.8M) but OCF +$6.7M. The difference is driven by: (a) non-cash SBC +$13.9M; (b) non-cash D&A +$2.6M; (c) inventory drawdown releasing cash (+$34.9M change in inventories); (d) restructuring charges that are partially non-cash or have deferred cash settlements
- **FY2022:** The massive -$180.7M OCF reflects Amarin building inventory during the generic transition period while simultaneously operating at an operating loss — a double cash drain

**Key insight:** AMRN's "true" cash burn rate is more accurately measured by OCF than GAAP net income. On an OCF basis, the company has already turned positive. FCF of +$9.3M in FY2025 and +$25.6M TTM (Q2 2025 - Q1 2026) suggests the cash base is stable, not melting. The management guidance of full-year 2026 positive cash flow is credible on current trajectory [S3, Judgment].

**Net cash is the dominant balance sheet story:** $302.6M (FY2025 year-end), $307.8M (Q1 2026). At ~$14.29-14.52 per share, net cash covers 94-95% of the recent ~$15.24 stock price. The operational franchise trades at an implied EV of $12-17M — a near-zero valuation. This is either the biggest opportunity (if the franchise has any residual value) or an appropriate reflection of a declining business burning through its cash balance (which is NOT occurring on an OCF basis) [S2, S3, Judgment].

---

#### 4. Balance Sheet Quality

##### Cash and Short-Term Investments: HIGH QUALITY

- **Cash and equivalents:** $134.7M (FY2025 year-end) [S1]
- **Short-term investments:** $167.9M (FY2025 year-end) [S2]
- **Total liquid:** $302.6M
- **Nature of investments:** Treasury bills, money market funds, short-duration investment-grade instruments (standard pharma treasury management); no meaningful credit risk [Judgment based on typical pharma treasury management practices; specific instrument disclosure in 10-K]
- **Debt:** $6.1M (lease obligations only; no bank debt, no bonds, no term loans) — effectively debt-free [S2]
- **Net cash per share:** $14.29 (FY2025) / $14.52 (Q1 2026) [S2]

**Assessment:** Cash quality is excellent. No liquidity risk. The primary risk is *rate of spend* — the company must continue operating near cash flow breakeven to preserve the cash pile. On current trajectory (FY2025 OCF +$6.7M, FY2026 target positive), the cash is durable.

##### Accounts Receivable: MODERATE CONCERN

- **AR balance (FY2025):** $126.8M against $213.6M annual revenue = **71 days sales outstanding (DSO)** [S2, Calculated]
- Normal pharmaceutical company DSO is typically 30-60 days for US wholesaler sales; 60-90 days for international partners
- The $126.8M AR is elevated relative to revenue run-rate, suggesting either: (a) large end-of-period shipments to partners; (b) normal international partner payment terms (30-90 days); (c) some collection risk

**[Judgment]:** DSO of ~71 days is at the high end of normal but not alarming for a company with significant international partner shipments on 60-90 day payment terms. No specific collection concerns identified. AR declined from $133.6M (FY2023) to $122.3M (FY2024) to $126.8M (FY2025) — broadly consistent with revenue trends.

##### Inventory: HIGH CONCERN (see also Section 1)

- **FY2025:** $195.9M (91.7% of annual revenue) [S1]
- **Composition:** ~50% North America, ~50% International (management disclosure in 10-K)
- **Write-down history:** Significant COGS inflation in FY2024 consistent with inventory write-downs; $336M→$259M→$166M→$196M trajectory shows high-then-declining trend as write-downs were taken and Recordati supply absorbed

**Inventory write-down risk going forward:** If North American inventory (estimated ~$98M) cannot be sold before product dating, write-downs will recur. Key variables: (a) US branded VASCEPA TRx trend — positive in Q1 2026 (+17%) is encouraging; (b) Recordati European supply absorption — ongoing; (c) remaining shelf life of existing inventory lots [S1, S2, Judgment].

##### Intangibles and Other Long-Term Assets

- **Intangible assets (net):** $13.4M (FY2025) vs. $18.6M (FY2024) — amortizing down [S2]
- **Other long-term assets:** $1.1M (FY2025) — material decline from $65.5M (FY2024) reflecting runoff of deferred tax assets, right-of-use assets from restructured leases, and/or prior-year prepayments [S2]
- **No goodwill** — Amarin has never made a significant acquisition; single-product organic company [S1]

##### Accumulated Deficit

- **$1.8B+ accumulated deficit** as of December 31, 2025 [S1]
- This reflects the company's entire history — years of R&D, the $300M+ REDUCE-IT trial investment, peak salesforce spending, and ongoing losses since patent invalidation
- The accumulated deficit does NOT affect cash or the ability to operate; it is primarily a carried-forward historical R&D and commercial investment. However, it eliminates the ability to pay dividends from retained earnings under Irish company law.

---

#### 5. Adversarial Research Sweep

This section systematically reviews negative research claims, litigation, regulatory investigations, and other adversarial risk factors for AMRN. Each item is assessed for status and materiality.

##### 5A. Short Selling Campaigns / Short Reports

**Finding:** AMRN has historically been a high short-interest stock during the peak commercialization period (2017-2021). Short reports targeted the REDUCE-IT trial design — specifically the mineral oil placebo controversy.

**The mineral oil placebo debate:** The REDUCE-IT trial used mineral oil as the placebo rather than a biological inert substance. Critics (notably published academic commentaries and short-side arguments) argued that mineral oil artifactually worsened lipid parameters in the placebo group, exaggerating VASCEPA's apparent benefit. The academic debate was vigorous 2018-2020. Counter-arguments: (a) FDA accepted the trial design; (b) 25% MACE reduction was consistent across multiple pre-specified subgroups; (c) >70 global medical societies adopted guideline recommendations [S1, S4].

**Current short interest:** ~3.03% of shares outstanding (~624,093 shares) as of June 2026 [S3] — LOW, not a high-short-interest situation. The short thesis has largely played out (revenue decline already realized).

**Assessment:** Short attack risk is minimal at current valuation (trading near cash value) and current short interest (~3%). The mineral oil controversy is settled academically and commercially; FDA approved the REDUCE-IT indication in 2019 and has not rescinded it. No active short campaigns identified.

##### 5B. Regulatory Investigations or FDA Actions

**Finding: None identified.**

- No FDA warning letters to Amarin in any filed disclosure [S1]
- No FDA enforcement action on VASCEPA quality or promotional practices identified
- DEA scheduling: N/A (VASCEPA is not a controlled substance)
- FDA REMS: Not required for VASCEPA
- European regulatory risk: VAZKEPA is under normal post-marketing pharmacovigilance; no safety signals identified that would affect approval [S1]

**Assessment:** Regulatory risk is LOW for the existing product. The primary regulatory risk is NOT enforcement but rather pricing policy (IRA, MFN proposals) and reimbursement access in new European countries.

##### 5C. Patent Litigation History and SCOTUS June 2026 Ruling

**This is the most significant legal development in AMRN's history as a publicly traded company:**

**Chronology:**
- 2015-2018: Amarin filed initial patent infringement suits against generic ANDA filers
- January 2020: Federal district court (D. Delaware) invalidated several MARINE indication patents as obvious; ruled that generic manufacturers could market ICE for TG ≥500 mg/dL indication
- January 2021: Generic ICE entered the US market (Hikma and others)
- Ongoing: Amarin pursued an *induced infringement* theory — even if generics could use a "skinny label" (omitting the REDUCE-IT indication), if generic manufacturers knew prescribers would prescribe for the CV indication, this constituted patent inducement
- May 2024: Federal Circuit Court of Appeals ruled in Hikma's favor on the inducement theory
- October 2025: Supreme Court granted certiorari
- June 4, 2026: Supreme Court ruled **9-0 for Hikma** — generic manufacturers' "skinny label" promotions did NOT constitute induced infringement [S3]

**What the ruling means:**
- Removes Amarin's ability to use patent litigation as a barrier to generic competition for the CV indication
- Does NOT invalidate Amarin's composition, formulation, or method patents entirely — it narrows what constitutes inducible infringement
- Does NOT immediately force any managed care contract changes; exclusivity contracts are commercial arrangements independent of patents
- **Does** open the door for more aggressive generic ICE promotion for the CV indication without litigation risk

**Securities litigation related to patent battles:** Multiple class action lawsuits were filed against Amarin at various times alleging securities fraud related to: (a) overstatement of patent protection strength; (b) statements regarding the REDUCE-IT trial design. These are disclosed in 10-K litigation section as ongoing or settled. No material adverse outcome has been identified in filed disclosures. Management believes existing reserves are adequate [S1].

**[Judgment]:** The SCOTUS ruling is the definitive legal resolution of the core patent battle. Amarin has lost. The US brand defense strategy must now rely entirely on commercial mechanisms (managed care exclusives, brand loyalty, product quality).

##### 5D. Securities Class Actions

**Finding:** Amarin has been subject to class action securities litigation in prior periods, primarily related to:
1. Allegations regarding REDUCE-IT trial disclosure (whether investors were adequately informed of the mineral oil placebo controversy)
2. Allegations regarding patent protection statements

**Current status:** The 10-K references ongoing patent litigation (LitigationCaseOne through Six per XBRL taxonomy). The 10-K notes that management believes contingent liabilities are adequately reserved but no specific settlement amounts are disclosed [S1].

**Assessment:** Securities litigation for a pharmaceutical company with a controversial clinical trial is common and does not represent an existential risk at the current market cap of ~$320M. The primary class action period (2019-2021, related to REDUCE-IT launch) appears to have substantially resolved without material financial impact on the company.

##### 5E. Inventory Write-Down Risk

**This is the most material unresolved financial risk:**

Current situation:
- $195.9M inventory vs. $213.6M annual revenue (91.7% ratio)
- ~50% North America (~$98M) — subject to US demand trends
- ~50% International (~$98M) — subject to Recordati launch pace and other partner absorption
- Product dating risk: Pharmaceutical finished goods have finite shelf life; lots approaching expiry must be written down

**Historical write-down evidence:**
- FY2024 COGS was $147.2M on $228.6M revenue (64.4% rate) vs. normal 40-43% rate — implied inventory write-down of $40-55M in FY2024 [Estimate from margin analysis; not separately disclosed]
- Inventory path: $336M (FY2023) → $166M (FY2024) → $196M (FY2025) — decline of $170M over two years, absorbed in COGS or product sales

**Forward write-down risk:**
- If North America inventory of ~$98M cannot be sold in 12-18 months, write-downs will recur
- The Q1 2026 +17% branded Rx improvement is encouraging but must be sustained
- Recordati European supply is beginning to absorb international inventory

**[Judgment]:** Inventory write-down risk is HIGH in probability of some write-down, MODERATE in magnitude (likely $15-40M rather than $100M+), and meaningful to COGS/gross margin presentation. This risk is partially mitigated by the positive US Rx trends in Q1 2026 and European supply ramp.

##### 5F. Going-Concern Analysis

**Finding: No going-concern language in auditor's report or management's discussion as of FY2025 10-K.**

This is notable given:
- Net losses in FY2023 (-$59M), FY2024 (-$82M), FY2025 (-$38.8M) — consecutive GAAP losses
- However, FY2025 OCF was POSITIVE (+$6.7M), and the company has $302.6M cash — equivalent to ~8-10 years of current annual cash burn at zero OCF

**[Assessment]:** Going concern is NOT a material risk at current cash level and trajectory. Even in a pessimistic scenario where OCF deteriorates to -$30M annually, the company has ~10 years of cash runway. The 10-K explicitly notes no going concern uncertainty [S1].

##### 5G. Related Party Transactions

**Finding:** 
- CEO Aaron Berg: Purchased 160,000 shares (pre-split adjusted: 8,000 post-split) at ~$0.64 (pre-split; ~$12.80 post-split equivalent) in August 2024 — open market purchase; disclosed via Form 4. This is insider buying, not a related-party concern [S3 via prompt context].
- Chairman Odysseas Kostas: Sarissa Capital background — Sarissa is a healthcare activist fund. Sarissa's involvement in AMRN may reflect activist agitation for the Barclays strategic review process. Sarissa may hold a significant beneficial interest that is disclosed in proxy/13D filings; this is a related-party disclosure point, not an accounting concern [S3 via prompt context].
- **Mochida collaboration:** Amarin licenses EPA IP from Mochida; milestone payments to Mochida are due upon achievement. This is an arm's-length licensing relationship, not a related-party transaction per SEC definitions [S1].

**[Assessment]:** No red-flag related-party transactions identified. Insider purchase by CEO is a positive signal. Sarissa Capital presence on the board via Kostas is consistent with the activist-driven Barclays strategic review process.

##### 5H. Additional Risk Factors Not Specifically Categorized Above

- **Irish company law:** Amarin is incorporated in England and Wales, tax-resident in Ireland. This creates complexity in dividend/distribution mechanics; may limit capital return options [S1]
- **No authorized generics:** Amarin has chosen NOT to launch an authorized generic — a deliberate strategy to protect brand premium. This means Amarin captures no share of the ~52% of ICE prescriptions going to generic products [S3]
- **Q2 2026 earnings risk:** Next earnings report ~July 29, 2026. Q2 2026 will be compared against Q2 2025's $72.7M revenue spike (Recordati deal close). YoY comparison will show a dramatic decline unless Recordati supply is growing at 50%+ rate. This creates a likely negative headline reaction risk even if underlying operations are improving [S2, Judgment]

---

#### 6. Red Flags / Green Lights Summary

##### Red Flags (Concerns Requiring Monitoring)

| # | Red Flag | Severity | Status |
|---|----------|----------|--------|
| 1 | Inventory of $195.9M (92% of revenue) with write-down history | HIGH | Active risk; Q1 2026 Rx improvement is partial mitigation |
| 2 | SCOTUS June 2026 ruling removes last US patent litigation lever | HIGH | Resolved; now a permanent structural constraint |
| 3 | Single-product dependence (VASCEPA/VAZKEPA 100% of revenue) | HIGH | Structural; no diversification possible without M&A |
| 4 | Revenue consensus declining (-14.7% FY2026 estimate) | MEDIUM | Street may be too pessimistic vs. Q1 2026 trajectory |
| 5 | $1.8B+ accumulated deficit | MEDIUM | Historical; does not affect operations but limits distributions |
| 6 | SBC $13.9M (36% of absolute operating loss; not in non-GAAP) | MEDIUM | Real economic cost often stripped in non-GAAP presentations |
| 7 | No salesforce globally — brand health dependent on partners | MEDIUM | Partner execution risk replacing commercial execution risk |
| 8 | 2026 AGM share issuance proposal | LOW-MEDIUM | Monitor for dilutive M&A or excess compensation |
| 9 | Q2 2026 earnings optical cliff (vs. $72.7M Q2 2025 spike) | LOW-MEDIUM | Communication/perception risk, not fundamental |
| 10 | Gross-to-net rebate estimation complexity | LOW | Standard branded pharma risk; audited annually |
| 11 | Irish incorporation — distribution mechanics complexity | LOW | Structural; not an acute risk |

##### Green Lights (Positive Quality Factors)

| # | Green Light | Strength |
|---|------------|----------|
| 1 | $302.6M net cash, debt-free — company cannot go bankrupt on current trajectory | HIGH |
| 2 | First positive OCF since 2023 (+$6.7M FY2025); positive FCF (+$9.3M) | HIGH |
| 3 | Q1 2026: first YoY revenue growth (+7.4%) in 4+ years | HIGH |
| 4 | Cost structure reset complete: SG&A -72% from peak; $70M annualized savings on track | HIGH |
| 5 | European IP to 2039 — 13-year protected franchise via Recordati | HIGH |
| 6 | VASCEPA branded Rx +17% YoY in Q1 2026; formulary exclusives maintained | MEDIUM-HIGH |
| 7 | CEO insider buying (160,000 shares at $0.64 equivalent Aug 2024) | MEDIUM |
| 8 | Barclays strategic review engaged — optionality on capital return / M&A | MEDIUM |
| 9 | No going-concern risk; 8-10+ year cash runway at zero OCF | HIGH |
| 10 | >70 global medical societies with updated IPE guidelines — durable clinical evidence base | MEDIUM |
| 11 | TTM FCF +$25.6M; improving trajectory | HIGH |

---

#### 7. Source Index

| Tag | Source |
|-----|--------|
| [S1] | Amarin Corporation Form 10-K, FY2025 (filed March 2, 2026); Accession 0001193125-26-085818; Period: Year Ended December 31, 2025; Risk factors, MD&A, litigation disclosures, inventory disclosures |
| [S2] | StockAnalysis.com — AMRN income statement, balance sheet, cash flow; June 2026; key statistics |
| [S3] | Analyst consensus and market data compilation; includes SCOTUS ruling (BioPharma Dive June 4, 2026), Q1 2026 earnings commentary, insider transaction disclosures (Form 4), short interest data (Fintel.io); June 2026 |
| [S4] | VASCEPA/AMRN Competitive Landscape analysis; compiled June 2026; includes REDUCE-IT trial design controversy background |

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AMRN/fundamental

## Navigation

- Overview: /stocks/amrn
- Financials (this page): /stocks/amrn/financials
- Thesis: /stocks/amrn/thesis
- Investment Memo: /memo/amrn
- Coverage universe: /stocks